56359-23-0Relevant academic research and scientific papers
NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS
-
Page/Page column 90, (2012/11/13)
Novel compounds of Formula I:or an enantiomer, diastereomer, tautomer, prodrug or salt thereof, wherein m, Q, T, U, V, ring A, X, Y, R3, R4, R4a, R5a, R5b, R5c, R5d, R5e, R6a, R6b, and R6c are defined herein, are provided which are TGR5 G protein-coupled receptor modulators. TGR5 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring TGR5 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the TGR5 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.
Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1
Goodnow, Robert A.,Hicks, Alexandra,Sidduri, Achyutharao,Kowalczyk, Agnieszka,Dominique, Romyr,Qiao, Qi,Lou, Jian Ping,Gillespie, Paul,Fotouhi, Nader,Tilley, Jefferson,Cohen, Noal,Choudhry, Satish,Cavallo, Gary,Tannu, Shahid A.,Ventre, Jessica D.,Lavelle, Danielle,Tare, Nadine S.,Oh, Hyesun,Lamb, Martin,Kurylko, Grazyna,Hamid, Rachid,Wright, Matthew B.,Pamidimukkala, Anjula,Egan, Thomas,Gubler, Ueli,Hoffman, Ann F.,Wei, Xin,Li, Ying L.,O'Neil, John,Marcano, Ruben,Pozzani, Karen,Molinaro, Tina,Santiago, Jennifer,Singer, Laura,Hargaden, Maureen,Moore, David,Catala, A. Robert,Chao, Lisa C. F.,Hermann, Gesine,Venkat, Radhika,Mancebo, Helena,Renzetti, Louis M.
experimental part, p. 3502 - 3516 (2010/09/08)
The inhibition of LTB4 binding to and activation of G-protein-coupled receptors BLT1 and BLT2 is the premise of a treatment for several inflammatory diseases. In a lead optimization effort starting with the leukotriene B4 (LTB4
LEUKOTRIENE B4 INHIBITORS
-
Page/Page column 20, (2010/10/03)
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, COPD
Leukotriene B4 Inhibitors
-
Page/Page column 16, (2009/04/24)
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, COPD
LEUKOTRIENE B4 INHIBITORS
-
Page/Page column 14, (2009/09/25)
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, COPD
LEUKOTRIENE B4 INHIBITORS
-
Page/Page column 30-31, (2009/07/18)
Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, COPD.
COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS
-
Page/Page column 21-22, (2008/06/13)
The present invention provides delivery agent compounds, compositions containing delivery agent compounds and an active agent and methods for delivering active agents, such as biologically or chemically active agents.
